Current status of primary prevention of sudden cardiac death with implantable cardioverter defibrillator in patients with chronic heart failure: – A Report From the CHART-2 Study –

Circulation Journal

Volumn 79, Issue 2, 2015, Pages 381-390

  Satake, Hiroyuki ^a   Fukuda, Koji ^a   Sakata, Yasuhiko ^a   Miyata, Satoshi ^a   Nakano, Makoto ^a   Kondo, Masateru ^a   Hasebe, Yuhi ^a   Segawa, Masato ^a   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Heart failure; Implantable cardioverter defibrillator; Sudden cardiac death

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; HEMOGLOBIN;

AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL; COHORT ANALYSIS; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREVALENCE; PRIMARY PREVENTION; PROSPECTIVE STUDY; SUDDEN CARDIAC DEATH; UREA NITROGEN BLOOD LEVEL; CHRONIC DISEASE; DEATH, SUDDEN, CARDIAC; FOLLOW UP; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHRONIC DISEASE; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84928229428     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0925     Document Type: Article

References (43)

1. Epstein AE, Ellenbogen KA, Estes NAM II, Freedman RA, Gettes LS, Gillinov AM, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Association Rhythm Society. Circulation 2012; 127: e283-e352, doi:10.1161/CIR.0b013e318276ce9b.
2. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006; 8: 746-837.
3. JCS Joint Working Group. Guidelines for non-pharmacotherapy of cardiac arrhythmias (JCS 2011): Digest version. Circ J 2013; 77: 249-274.
4. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.
5. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237.
6. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM UI, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/ AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117: e350-e408, doi:10.1161/CIRCUALTIONAHA.108.189742.
7. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999; 341:1882-1890.
8. Kadlish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151-2158.
9. Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, et al. Amiodarone versus implantable cardioverter-defibrillator: Randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT. J Am Coll Cardiol 2003; 41: 1707-1712.
10. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: A meta-analysis of randomized controlled trials. JAMA 2004; 292: 2874-2879.
11. Tanno K, Myoshi F, Watanabe N, Mnoura Y, Kawamura M, Ryu S, et al. Are the MADITII criteria for ICD implantation appropriate for Japanese patients? Circ J 2005; 69: 19-22.
12. Shiga T, Hagiwara N, Ogawa H, Takagi A, Nagashima M, Yamauchi T, et al. Sudden cardiac death and left ventricular ejection fraction during long-term follow-up after acute myocardial infarction in the primary percutaneous coronary intervention era: Results from the HIJAMI-II registry. Heart 2009; 95: 216-220.
13. Shiba N, Nochioka K, Mura M, Kohno H, Shimokawa H. Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan: First report from the CHART-2 Study. Circ J 2011; 75: 823-833.
14. Nochioka K, Sakata Y, Takahashi J, Myata S, Miura M, Takada T, et al. Prognostic impact of nutritional status in asymptomatic patients with cardiac diseases: A report from the CHART-2 study. Circ J 2013;77:2318-2326.
15. Sakata Y, Miyata S, Nochioka K, Mura M, Takada T, Tadaki S, et al. Gender differences in clinical characteristics, treatment and long-term outcome in patients with stage C/D heart failure in Japan: A report from the CHART-2 study. Circ J 2014; 78: 428-435.
16. Mura M, Sakata Y, Myata S, Nochioka K, Takada T, Tadaki S, et al. Usefulness of combined risk stratification with heart rate and systolic blood pressure in the management of chronic heart failure: A report from the CHART-2 study. Circ J 2013; 77: 2954-2962.
17. Yancy CW, Jessup M, Bozlurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA Guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: 1810-1852.
18. Olgin AE, Zipes DP. Ventricular tachycardia, ECG recognition. In: Braunwald E, editor. Heart disease, 7th edn. Philadelphia: Saunders, 2005; 841-842.
19. Kearney MT, Fox KA, Lee AJ, Brooksby WP, Shah AM, Flapan A, et al. Predicting sudden death in patients with mild to moderate chronic heart failure. Heart 2004; 90: 1137-1143.
20. Uretsky BF, Thygesen K, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: Results from the Assessment of Treatment with Lisinopril And Survival (ATLAS) trial. Circulation 2000; 102: 611-616.
21. Moss AJ, Hall WJ, Cannom SC, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933-1940.
22. Shiba N, Shimokawa H. Chronic heart failure in Japan: Implications of the CHART studies. Vasc Health Risk Manag 2008; 4:103-113.
23. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol study II (CIBIS-II): A randomised trial. Lancet 1999; 352:9-13.
24. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 80: 257-266.
25. Pitt B, Segal R, Martinez FA, Meurers G, Cowley A, Thomas I, et al. Randomised trial of losartan versus Captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-752.
26. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
27. Ushigome R, Sakata Y, Myata S, Miura M, Takada T, Tadaki S, et al. Improved long-term prognosis of patients with dilated cardiomyopathy: A report from the CHART studies. Circ J 2014; 78(Suppl I): 549.
28. Greeberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML, et al. Analysis of mortality events in the multicenter automatic defibrillator implantation trial (MADIT-II). J Am Coll Cardiol 2004; 43: 1459-1465.
29. Abildstrom SZ, Ottesen MM, Rask-Madsen C, Andersen PK, Rosthoj S, Torp-Pedersen C, et al. Sudden cardiovascular death following myocardial infarction: The importance of left ventricular systolic dysfunction and congestive heart failure. Int J Cardiol 2005; 104: 184-189.
30. Solomon SD, Zelenkofske S, McMurray JJ, Finn PV, Velazquez E, Ertl G, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005;352:2581-2588.
31. Hoang A, Shen C, Zheng J, Taylor S, Groh WJ, Rosenman M, et al. Utilization rates of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death: A 2012 calculation for a mid-western health referral region. Heart Rhythm 2014; 11: 849-855.
32. Parkash R, Sapp JL, Basta M, Doucette S, Thompson K, Gardner M, et al. Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit. Circ Arrhythm Electrophysiol 2012; 5: 706-713.
33. Hernandez AF, Fonarow GC, Liang L, Al-Khatib SM, Curtis LH, LaBresh KA, et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA 2007; 298: 1525-1532.
34. Gravelin LM, Yuhas J, Remetz M, Radford M, Foley J, Lampert R. Use of screening tool improves appropriate referral to an electro-physiologist for implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. Circ Cardiovasc Qual Outcomes 2011;4:152-156.
35. Birnie DH, Sambell C, Johansen H, Williams K, Lemery R, Green MS, et al. Use of implantable cardioverter defibrillators in Canadian and US survivors of out-of-hospital cardiac arrest. CMAJ 2007; 177: 41-46.
36. Sadarmin PP, Wong KC, Rajappan K, Bashir Y, Betts TR. Barriers to patients eligible for screening investigations and insertion of primary prevention implantable cardioverter defibrillators. Europace 2014; 16: 1575-1579.
37. Dagres N, Hindricks G. Risk stratification after myocardial infarction: Is left ventricular ejection fraction enough to prevent sudden cardiac death? Eur Heart J 2013; 34: 1964-1971.
38. Borleffs CJW, van Rees JB, van Welsenes GH, van der Velde ET, van Erven L, Bax JJ, et al. Prognostic importance of atrial fibrillation in implantable cardioverter-defibrillator patients. J Am Coll Cardiol 2010;55:879-885.
39. Pedersen OD, Abildstrom SZ, Ottesen MM, Rask-Madsen C, Bagger H, Kober L, et al. Increased risk of sudden and non-sudden cardiovascular death in patients with atrial fibrillation/flutter following acute myocardial infarction. Eur Heart J 2006; 27: 290-295.
40. Grimm W, Glaveris C, Hoffmann J, Menz V, Muller HH, Hufnagel G, et al. Arrhythmia risk stratification in idiopathic dilated cardiomyopathy based on echocardiography and 12-lead, signal-averaged, and 24-hour Holter electrocardiography. Am Heart J 2000; 140: 43-51.
41. Watanabe J, Shinozaki T, Shiba N, Fukahori K, Koseki Y, Karibe A, et al. Accumulation of risk markers predicts the incidence of sudden death in patients with chronic heart failure. Eur J Heart Fail 2006; 8:237-242.
42. Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, et al. Risk stratification for primary implantation of cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008; 51: 288-296.
43. Carson P, Anand I, O'Connor C, Jaski B, Steinberg J, Lwin A, et al. Mode of death in advanced heart failure: The Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) Trial. J Am Coll Cardiol 2005; 46: 2329-2334.